| CHINESE | JAPANESE | KOREAN |
  Home         Investment Guide          News          Special Coverage          News in Retrospect          Contact Us
  Industries & Enterprises  | Tourism & Leisure  | Education & Schools  | Infrastructure & Ecology  | Life & Culture  | Authorities & Policies
 
  SIP strives to set a g...
8d9c841d1380ab689083964b910bde1.jpg
 
  Quicken pace toward a ...
66f58ee66a7e596d594a48ad34c7952.jpg
 
  Enterprises in Jinji L...
0a6226b09768b42273aa446b830a1e5.jpg
 
  Expatriates help fight...
d7342d72fc662ac7e5bdcdd96b758c1.jpg
 
  SISPARK employs high t...
WechatIMG28.png
 
 
Current Position: Home page > News in Retrospect > Year2018
  Print page Text size:  
 


Crystal Pharmatech raises over RMB 100 million in Series B round


Crystal Pharmatech, an SIP-based technology-driven contract research organization (CRO) that focuses on materials science and engineering for drug development, announced on Dec 25, 2018 that it has raised over RMB 100 million in Series B fundraising. Shiyu Capitals led the round with the participation of Cowincapital and SIP Oriza Seed Fund Management Co Ltd.

Started out in SIP's BioBAY in 2010, the CRO has established partnerships with more than 500 pharmaceutical companies across the world, including many top-ranking drug makers home and abroad. It operates R&D centers in Beijing (China), New Jersey (the United States) and Toronto (Canada) to provide all-around technical support for new drug discovery, development and marketing. The raised fund is expected to help enhance its R&D ability and better its services.


December 29, 2018

 
 
   
 
  FEATURED VIDEOS  
     
   
  Suzhou Industrial Park Video  
  Watch